Chanticleer — Sonnet BioTherapeutics Holdings — Investor Presentation (June 2024)
33 slides from Chanticleer's investor presentation, Jun 14, 2024
Slide 1: Powering a New Wave of Immune Therapeutics
§ SONNET BioTherapeutics POWERING A NEW WAVE OF IMMUNE THERAPEUTICS Corporate Presentation 2 quarantee ttle perfomance.
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements about Sonnet BioTherapeutics based on management's current expectations which are subject to known and unknown uncertainties and risks. Words such as “anticipated,” “initiate,” “expect,” “intend,” “plan,” “believe,” “se
Slide 3: Powering a New Wave of Immune Therapeutics
Powering a New Wave of Immune Therapeutics CORPORATE FOCUS Prioritize development of assets with partnering interest Cost-cutting initiative to reduce operating expenses by approximately 30% Existing material supply agreement with Roche and J8J pipeline evaluation offer licensing expansion opportuni
Slide 4: Pipeline Overview
Pipeline Overview PROGRAM INDICATIC PRECLIN SON-1010 (1L12-F,AB) Solid Tumors | f Platinum-Resistant Ovarian 5 | Seemoneays) Ee ahs, iy BL SON-1210 (1L12-F,AB-1L15) Solid Tumors a < pr SON-1411 (L18-F,AB-1L12) Solid Tumors SON-1400 (1L18-F,AB) Solid Tumors Chemotherapy Induced Perioheral Neuropathy
Slide 5: Sonnet Pipeline Targets
Sonnet Pipeline Targets Multiple Points of Intervention IL-18 i Naive ‘Tumor Antigen Nene e Antigen 7 Fragments Lymph | Tumor Mature Dendritic La enn permaen \ Antigen Effector cells: feceptors 1. Activate other immune cells ef a } 2. Kill “target cells” a Activated T-cell Memory cells: Immature 4.
Slide 6: FHAB Platform Technology
§ SONNET F,AB PLATFORM TECHNOLOGY
Slide 7: Sonnet's Technology Advantage
Sonnet’s Technology Advantage One owe payonds amb otaged wth, ‘mata ca -* wr s0N-1010 nso ‘Albumin Aa Son hy Fefinto x: 9 turer cat sz SG y, Ly AW Newropi Atointinas ace ‘aria seater Se eal Dendritic cell Albumin binds Fein or the GP60 receptor on tumor vessel walls, ‘then is transported into the TM
Slide 8: FHAB: Superior Uptake and Retention in Tumor Tissue
F,,AB: Superior Uptake and Retention in Tumor Tissue An in vivo demonstration of SPARC-mediated binding with optimized retention using albumin F,AB alone Anti-TGFB, no FAB Anti-TGFB-F,AB her Results show F,,AB enhanced EPR = Efficacy Western blot of Mouse 471 (TGFB positive tumor@150mm3) extracts fr
Slide 9: Biodistribution Profile Using Radiolabeled mIL12-FHAB and mIL12
Biodistribution Profile Using Radiolabeled mIL12-FHAB and mIL12 mlL12-FHAB Accumulates in Tumor and Draining Lymph No Tumor Biodistribution Lymph Nodes Biodistribution re 25 1 2 £ £ gO? Bis 206 6 Doe a1 & zg 02 Os o 0 GHR 24HR 48 HR 96 HR 6HR 24HR agHR 96 HR Time Time eszemiL12 mB9ze-mIL12-HAB Se 89
Slide 10: FHAB: Enhanced Pharmacokinetic Characteristics
FAB: Enhanced Pharmacokinetic Characteristics Comparing the pharmacokinetic characteristics of naked IL-12 and IL-15 versus the same interleukins linked to Sonnet’s FyAB Method: 8 mice C57B/ TP, age 9.5 weeks, dose IV, sacrificed @ 5, 15, 30 mins, 1, 2, 4, 8, 24 & 48 hrs. Serum tested by ELISA. © IL
Slide 11: FHAB: Defining A Better Platform Technology
FAB: Defining A Better Platform Technology Mn SL Sonnet F,AB & © pee Feige > — DNA/ Viral Albumin Binding : BFE PS QA Weal Gane Terany 7 Fan rey ATTRIBUTES QUALIFIER ATTRIBUTES QUALIFIER ATTRIBUTES QUALIFIER ATTRIBUTES QUALIFIER Mono or Bi- Mono or Bi- Mode Mow og Mode Mono Mode Nene Mode Mono a prs
Slide 12: FHAB: Preclinical Proof-of-Concept
() Biotherapeufics F,AB: PRECLINICAL PROOF- OF-CONCEPT
Slide 13: SON-1010: Reduces Tumor Growth in Mice
SON-1010: Reduces Tumor Growth in Mice 1L12-F,,AB (1.3ug) vs IL-12 (30g) in B16F10 Melanoma Tumor Volume mm? 1500 1000 + Placebo 4 1L12-FHAB (1.3119) = Molar 0.9ug of 1L-12 t IL-12 (30ng) 1:30 ratio of IL-12 2887 1996 Days 10 IL-12 (1g) and IL12- FAB (1.39) are molar equivalent and have similar bioa
Slide 14: SON-1210: Bispecific Activity
SON-1210: O 1 Bispecific Activity Lymphoblast proliferation assay (IL-12) IFN-y release assay (IL-12) CTLL-2 proliferation assay (IL-15) 2.59) mgm IL12-F,,AB-ILIS =P 1115 (RAD ref (i 1L12-F,AB-ILIS zo e ® 1L12 (R&D ref) ° WH 1112 (Rad ref, asa ® 112-F,AB-IL15 Bo 12-F,aB 20000 15000 0000 an 10 108 10
Slide 15: Flow Cytometry Analysis: Comparison of Efficacy
Flow Cytometry Analysis 5 1L12-FHAB (119) 1L12-FyAB-IL15 (51g) | 1L18-FHAB4L12 (5ug) Comparison of Efficacy Tumor & Spleen Inhibition 37% Inhibition 78% Inhibition 65% Immune Cell Type Day 5, TV ~400mm* Tumor | Spleen | Tumor | Spleen | Tumor | Spleen Cell Population T cells 08 1.0 05 09 12 0.9 CD4+
Slide 16: Positioned For Clinical Development
Positioned For Clinical Development B16F10 mouse model % Inhibition -@ Tumor Bearing Placebo 99% © Tug IL12-F,ABILIS 78% © Sug IL1ZFYABILIS 41% © Sug IL15 and IL12 Ref 91% -® 5 yg IL12-ABD-L15 (x3) Tumor Volume (mm*) 900: Therapeutic ‘eo Payload A SON-1210 300: Binds albumin 6 in circulation ix 1 2
Slide 17: IL-18 and IL-12 Co-activate Immune Cells in the TME
IFNy ee — ,— 1L-18°°* and IL-12 co-activate immune cells inthe TME I-18 BP extend halflife Albumin binds Albumin binds GP60 in tumor SPARC in the vessels TMEatlow pl IL-18 increases CXCL9 & CXCL10 expression, which increases NK, CD8, and CD4 T-cell infiltration into tumors, while IL-12 augments T-ce
Slide 18: SON-1010: Clinical Program
() Biotherapeufics SON-1010: CLINICAL PROGRAM
Slide 19: Clinical Program
Clinical Program: SB101/SB102 Stu $B102: SAD for PK/PD/FACS in ; oaate ore Levers) | (=200 narkg Healthy Volunteers ThiL-12) 300 / 1200 ngikg wks 180 ng/kg (= 800 ng/kg rhiL-12) ng/kg aSwks [pose ter 150/540 Interim PX Analysis & glkg a3wks 50 nghkg Modeling 6 per cohort 180/300 TET] wise 180/300 *
Slide 20: SB101: Safety Data
SB101: Safety Data 50 ng/kg 150 ng/kg 150 > 300ngikg | 1505 300ngikg | 150 540 ng/kg Tachycardia (Grade 1) 1 (33.3) Nausea (Grade 1) 183.3) Chills (Grade 1) 183.3) 1(33.3) Fatigue (Grade 1) 133.3) 1(83.3) Injection site pain (Grade 1) 1 (33.3) 3.(100.0) Pain (Grade 1) 1(83.3) Pyrexia (Grade 1) 183.3
Slide 21: SB101 Cytokine Assay Results
SB101 Cytokine Assay Results 10005 IFN-y 100- IL-40 Primary PD parameters included IFNy, IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, and TNFa, assayed using the MSD platform + Increases in IFNy (showing an IL-12 effect and potential for tumor control) were dose-related, controlled, and prolonged, * —SON-10
Slide 22: SON-1010 Interim PK Analysis after Cohort
SON-1010 Interim PK Analysis after Cohort 3 » Typical dose-related increases were seen with SON-1010, with single compartment kinetics in cancer and the potential for two compartments in healthy volunteers » The preliminary geometric mean elimination half-life (ty,) was 113 hours in SB101, compared
Slide 23: Unaud
Unaud oe 200.970 350->540 1509200 150-7200 80reh SOngKE regen neha Days since Dosing The swimmers plot shows the status for each patient and whether they had PD or SD at study entry. If patients are clinically stable and have tumor growth that might represent either tumor inflammation (a positive ef
Slide 24: SB101 Clinical Program: High Level Summary
SB101 Clinical Program: High Level Summary » Preliminary PK modeling suggests ty, in humans is ~120 hrs emia Q Compares favorably with rhIL-12 ty, of 5-12 hrs? » No Dose Limiting Toxicities to date in 17 patients » Mostly mild with very few more significant AEs a AEs consistent with published litera
Slide 25: SB221: MTD/RP2D + ICI Proof of Concept
SB221: MTD/RP2D # ICI Proof of Concept Update as of 3/27/24 = 7 7 i SONG + ICI (PROC) | 30/1200! “ | son-1010@ j af | sensi a. / Vora | E5| SONS + ICI (PROC) | 300/850 SON-1010 + ICI @Part 1 RP2D SON-1010 aA. N\ Binds abun in circulation E4{ SON4 + ICI (PROC) | 300/600 $8221 RP2D Pal Expansion E3[ S
Slide 26: SON-1010: Clinical Update 2024
SON-1010: Clinical Update 2024 SON-1010 can be used as monotherapy or combined with an anti-PD-L1; dose escalation has been safe to date The Phase 1 studies have together enrolled 61 subjects > Patients have received up to 25 cycles of SON-1010 as monotherapy and 10 cycles of SON-1010 with atezolizu
Slide 27: Proposed Development Pathway
oils tone Proposed Development Pathway id Effic Mouse Tumor Model: NHP =Tox, PK, Combo anti-PD1 & Repeat dose mIL12-F,AB ——S —/ SB101, SB102 $B221 Studies Study Phase (w pop PK) MTD in Phase 1b/2a Phase 2b 7 advanced combo in. Dose GD solid tumor, PROC Finding iad ‘SAD in NHV POC (E-R) NM . Phase 3
Slide 28: SON-1010 in Combination with atezolizumab (Tecentriq)
() BioTherapeutics SON-1010 in Combination with atezolizumab (Tecentriq®) » $B221 Study: Collaboration with Roche/Genentech? » Phase 1b/2a adaptive design study to assess the safety, tolerability, PK/PD, and POC of SON-1010 in combination with atezolizumab in patients with platinum-resistant ovarian
Slide 29: Next Generation Oncology Platform (FHAB)
Next Generation Oncology Platform (F,,AB) Q Confers both tumor targeting and enhanced pharmacokinetics (PK) Fully human protein sequence, and thus, no predicted immunogenicity First immune activator with tumor-targeting functions on a proprietary F;,AB platform Encouraging preclinical data in a canc
Slide 30: SON-080 (Low-Dose IL-6): CIPN and DPN
§ SONNET SON-080 (LOW-DOSE IL-6) CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY AND DIABETIC PERIPHERAL NEUROPATHY
Slide 31: IL-6 Is Neurotrophic
IL-6 Is Neurotrophic Neuron — Nerve function Protects Neurons from excitotoxic injury Reinstates nerve conduction velocity Sensory Nerve Conduction Velocity | af | Eo Gol Gipatn Gita cpa ice “While Spano asta) Myelin sheet Stimulates production of Myelin Binding Protein (MBP) _- Sensory function Nor
Slide 32: IL-6: Safe and Well Tolerated at the Target Dose
IL-6: Safe and Well Tolerated at the Target Dose Phase I/II Clinical Data PATIENT DURATION Thrombocytopenia n= 213; all types also including Grade lII/V cancer 10 independent Phase I/II studies Diverse antineoplastic therapies 0.25-32 ug/kg/day, or 5-20 jig/kg/TIW SC Up to 10 weeks SSQNNET BioTherap
Slide 33: Corporate Summary
Corporate Summary Immune Oncology Immune stimulation using a proprietary Fully Human Albumin Binding (F;,AB) platform to target the tumor microenvironment Safety Single dose of SON-1010 shown to be safe and well tolerated in healthy volunteers. Multiple doses of SON-1010 shown to be safe with early
Sonnet BioTherapeutics Holdings — Investor Presentation (June 2024) on 6ix